Skip to main content
Signal8

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

$INCYPress releaseJun 8, 2026, 7:00 AM ETRead the release

Incyte has entered a definitive agreement to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion in upfront cash. The deal adds VGA039, a Phase 3 investigational monoclonal antibody for von Willebrand disease, to Incyte’s hematology portfolio. VGA039 is a first-in-class subcutaneous therapy with Breakthrough Therapy designation. Star Therapeutics is eligible for up to $750 million in additional sales milestones, bringing total potential consideration to $2.0 billion.

Key figures

Deal Value Usd
1250000000
Expected rd charge
$1.25 billion
Milestone payments
$750 million
Total potential consideration
$2.0 billion

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.